Medicare AdvantagePrior AuthMedium impact
MA08.082p, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 20, 2026
We identified it
Jun 19, 2026
Summary
Updates to medical necessity criteria and billing codes for several white blood cell growth factors including Ryzneuta, Rolvedon, Neulasta and their biosimilars. This policy affects Medicare Advantage coverage and coding requirements for these specialty oncology medications.
Action Required
By April 20, 2026: Billing team must review updated medical necessity criteria for Efbemalenograstim alfa-vuxw (Ryzneuta), Eflapegrastim-xnst (Rolvedon), Pegfilgrastim (Neulasta) and related biosimilars. Update prior authorization workflows and coding guidelines in billing system for Medicare Advantage patients receiving these medications. Review full policy at source URL for specific documentation requirements.